Showing 1711-1720 of 3239 results for "".
- FDA Warns of Severe Adverse Events with Application of Picato (ingenol mebutate) Gel; Requires Label Changeshttps://practicaldermatology.com/news/fda-warns-of-severe-adverse-events-with-application-of-picato-ingenol-mebutate-gel-requires-label-changes/2458878/The FDA released a Drug Safety Communication to warn about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is approved to treat actinic keratosis. The FDA said it also received reports of cases involving sev
- Genentech Initiates Phase III Trial of Rituximab in Pemphigus Vulgarishttps://practicaldermatology.com/news/genentech-initiates-phase-iii-trial-of-rituximab-in-pemphigus-vulgaris/2458885/Genentech has initiated a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV). The aim of the PEMPHIX study is to determin
- GW School of Medicine and Health Sciences Announces New Dermatology Residency Programhttps://practicaldermatology.com/news/gw-school-of-medicine-and-health-sciences-announces-new-dermatology-residency-program/2458895/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) is pleased to announce a new dermatology residency program that began on July 1, 2015. This unique training experience is open to national and international medical students, who will learn to provide the
- Nuvo Research Granted US Patent for Topical Onychomycosis Formulationhttps://practicaldermatology.com/news/nuvo-research-granted-us-patent-for-topical-onychomycosis-formulation/2458896/The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2
- Galderma Receives FDA Approval for Epiduo Forte for Acnehttps://practicaldermatology.com/news/galderma-receives-fda-approval-for-epiduo-forte-for-acne/2458909/The FDA approved Galderma’s antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel is the first combination of these strengths of the retinoid, adapalene, and benzoyl peroxide, developed for
- Heliocare Earns NSF Good Manufacturing Practice Registration For IFC Manufacturing Facilityhttps://practicaldermatology.com/news/heliocare-earns-nsf-good-manufacturing-practice-registration-for-ifc-manufacturing-facility/2458911/Ferndale Healthcare, Inc.’s IFC manufacturing facility for its Heliocare® brand is now a Good Manufacturing Practices (GMP) facility registered by NSF International, an independent organization recognized as the world leader in standards development, product certification, ed
- Research Identifies Gene Linked to Melanoma Growth, Worse Outcomeshttps://practicaldermatology.com/news/research-identify-gene-linked-to-melanoma-growth-worse-outcomes/2458925/High levels of a specific protein linked to gene expression are associated with worse outcomes in melanoma, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell. Research shows that the protein, called H2A.Z.
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten
- FDA Clears Alevicyn SG Antipruritic Spray Gel from Oculus Innovative Scienceshttps://practicaldermatology.com/news/fda-clears-alevicyn-sg-antipruritic-spray-gel-from-oculus-innovative-sciences/2458933/The FDA granted 510(k) clearance to Oculus Innovative Sciences, Inc. for Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications. The Alevicyn SGprescription product, using Microcyn(R) Technology, is indicate
- Galderma Introduces ASPIRE Loyalty Program for the Aesthetic Industryhttps://practicaldermatology.com/news/galderma-introduces-aspire-loyalty-program-for-the-aesthetic-industry/2458936/Galderma launched ASPIRE Galderma Rewards, a new loyalty program for its aesthetic brands. ASPIRE is unique in that it serves both both US healthcare professionals and consumers in one integrated program. ASPIRE rewards its members with significant savings across the entire aesthetic prod